Effects of ethyl-icosapentate on renal function in patients with chronic kidney disease

Effects of ethyl-icosapentate on renal function in patients with chronic kidney disease - Effects of ethyl-icosapentate on renal function in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008619

Enrollment

Registered

2012-08-06

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease with hyperlipidemia

Interventions

Add-on Ethyl-icosapentate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Dyslipidemic patients with chronic kidney disease. 2. Patients who are capable of understanding the informed consent and are agree to join this study.

Exclusion criteria

Exclusion criteria: 1. Patients who are easy to bleed. 2. Patients treated with ethyl icosapentate at the time of study initiation. 3. Patients who are judged as ineligible by clinical physicians.

Design outcomes

Primary

Measure	Time frame
Serum lipid: (F) LDL, HDL, (F) LDL/HDL ratio, total cholesterol, Triglyceride Renal function: proteinuria(albuminurina), serum Creatinine , eGFR(estimated Glomerular Filtration Rate) , serum cystatin C, Urinary Liver-Type Fatty Acid Binding Protein, Fraction of serum fatty acids(EPA/AA ratio)	—

Secondary

Measure	Time frame
high sensitivity CRP, RLP-C,VLDL apolipoprotein(A1,B,E),8-OHDG	—

Countries

Japan

Contacts

Public ContactHitoshi Suzuki

Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology

shitoshi@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026